Arm just unveiled its first in-house chip. Raymond James says buy the stock

Raymond James upgraded Arm to Outperform and set a $166 price target, implying ~23% upside after Arm unveiled its first in-house AGI CPU; shares jumped ~13% in premarket trading. The AGI CPU, co-developed with Meta and targeted at AI inference and agentic workloads, is positioned for broad adoption by hyperscalers and firms (Alphabet, Microsoft, Meta, Amazon and others). Arm executives forecast roughly $1 billion incremental revenue through FY2028, rising to ~$15 billion by FY2031, and Raymond James cites up to 2x performance vs x86 in high-end reference configurations.

Analysis

Arm’s move into direct product economics changes the unit-economics levers investors should be modeling: margins will be driven less by royalty share rates and more by product mix, ASP trajectory, and foundry economics (node/wafer costs, yield curve). That transition amplifies operating leverage but also introduces inventory and gross-margin volatility tied to multi-nanometer supply cycles — model gross margins on a scenario basis rather than a single uplift.

Competitive dynamics will play out along two axes: software/hardware co-optimization and supply allocation. Faster per-rack data‑plane CPU throughput reshuffles where hyperscalers invest (more rack compute, less raw accelerator sprawl), creating follow-on demand for networking and edge players that can absorb higher throughput (benefits to Cloudflare-analogues and packet-processing vendors). Conversely, if hyperscalers internalize designs or secure exclusive deals, market access and pricing power for third-party adopters compress rapidly.

Key catalysts and risks are timing and technical proof-points: expect sentiment moves within days of benchmark/public design-wins, but sustainable revenue / margin recognition comes in quarters-to-years as wafers, software stacks, and OEM qualification complete. Tail risks: disappointing real-world perf, foundry capacity rationing, or unfavorable commercial terms from anchor customers could erase near-term multiple expansion; regulatory/export frictions or accelerating hyperscaler vertical integration would similarly compress upside.

Against consensus optimism, the market may underprice the combination of foundry dependency and customer concentration while overpaying for early runway. A prudent staging of exposure that monetizes near-term sentiment but preserves downside protection is warranted given asymmetric execution risk over 12–36 months.

Key Decisions for Investors

• Long ARM equity (size 2–4% NAV): stagger entries over 2–6 weeks to average in; target 30–40% upside over 6–12 months, hard stop at -15% from entry to reflect execution risk.
• Buy ARM 6–9 month call spread (buy near‑ATM, sell ~30% OTM) to capture continued multiple expansion while capping premium; goal return 2–4x if product adoption headlines sustain — max loss = premium paid.
• Thematic longs: initiate positions in NET and FFIV (each 1–2% NAV) as 6–18 month plays on increased data‑plane demand; take profits at +35–50%, stop at -20%.
• Tail hedge: purchase out‑of‑the‑money ARM puts (9–12 month) sized to offset 50% of the long equity position in case of foundry/order reallocation or a major anchor customer pullback.